Commodore Capital LP 13D and 13G filings for Viridian Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-04-11 5:15 pm Purchase | 2025-04-04 | 13G | Viridian Therapeutics, Inc. VRDN | Commodore Capital LP | 4,300,000 5.300% | 2,375,926 (+123.48%) | Filing |
| 2024-02-14 4:05 pm Purchase | 2023-12-31 | 13G | Viridian Therapeutics, Inc. VRDN | Commodore Capital LP | 1,924,074 3.700% | 552,735 (+40.31%) | Filing |
| 2023-02-14 4:06 pm Purchase | 2022-12-31 | 13G | Viridian Therapeutics, Inc. VRDN | Commodore Capital LP | 2,020,166 5.000% | 2,020,166 (New Position) | Filing |
| 2023-02-14 4:05 pm Purchase | 2022-12-31 | 13G | Viridian Therapeutics, Inc. VRDN | Commodore Capital LP | 2,732,567 5.900% | 2,732,567 (New Position) | Filing |
| 2022-05-19 4:30 pm Purchase | 2022-05-09 | 13G | Viridian Therapeutics, Inc. VRDN | Commodore Capital LP | 1,371,339 5.000% | 1,371,339 (New Position) | Filing |